Angelica Welch

Articles

Expert Shares Insight on Patient Selection for RT in Breast Cancer

February 2nd 2017

Welela Tereffe, MD, discusses the current state of radiation therapy in breast cancer and the importance of a multidisciplinary approach.

Molecular Testing in Breast Cancer to Answer More Questions in 2017

January 31st 2017

Jenny C. Chang, MD, discusses the significance of molecular testing in breast cancer and how it will lead to an improvement in treatment approaches in 2017 and beyond.

MOR208 Combo Regimens Show Early Promise in CLL

January 27th 2017

Jennifer A. Woyach, MD, discusses the preliminary results of an ongoing phase II trial of MOR208 combination regimens in chronic lymphocytic leukemia.

Underreporting of Immunotherapy-Related AEs a Concern in RCC

January 24th 2017

Neeraj Agarwal, MD, discusses a trend of underreporting and underemphasizing toxicities associated with PD-1 inhibitors in the treatment of patients with renal cell carcinoma.

Researcher Hopes Vaccines Can Improve Immunotherapy Outcomes in RCC

January 23rd 2017

Tian Zhang, MD, discusses the development of vaccines to treat patients with renal cell carcinoma.

Rini Stresses Axitinib Remains Significant in RCC

January 20th 2017

The tyrosine kinase inhibitor axitinib has been standard in the management of advanced renal cell carcinoma for about 5 years now, but the emergence of new agents has made some members of the oncology community concerned that its significance will be overlooked in favor of more recently approved treatments.

Dual HER2-Blockade Plus AI Shows Promise in HER2+/ER+ Breast Cancer

January 17th 2017

Data from the phase II PERTAIN trial presented late last year at the 2016 San Antonio Breast Cancer Symposium showed that adding an aromatase inhibitor (AI) to pertuzumab and trastuzumab extended progression-free survival by over 3 months versus trastuzumab plus an AI in patients with HER2-positive, HR-positive locally advanced or metastatic breast cancer.

Researcher Discusses Optimal Sequencing in Advanced RCC

January 16th 2017

Guru Sonpavde, MD, discusses challenges with sequencing in advanced renal cell carcinoma and his vision for the field going forward.

Yardley Discusses Evolving Role of Nab-Paclitaxel in TNBC

January 16th 2017

Denise A. Yardley, MD, discusses the phase II tnAcity trial, the current role of nab-paclitaxel in triple-negative breast cancer, and the potential for using nab-paclitaxel in combination with immunotherapy in this setting.

Efforts Continue to Expand Immunotherapy Impact in Sarcoma

January 12th 2017

Researchers are hoping the immunotherapy revolution occurring across several cancer types will extend to the field of sarcoma.

Avelumab Shows Promise as Frontline Immunotherapy Alternative in NSCLC

January 11th 2017

Immunotherapy is quickly becoming a mainstay in the frontline setting for the treatment of patients with metastatic non–small cell lung cancer.